MeiraGTx (NASDAQ:MGTX – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Profitability
This table compares MeiraGTx and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MeiraGTx | -140.31% | -1,065.47% | -53.33% |
| Connect Biopharma | N/A | -88.21% | -74.26% |
Risk and Volatility
MeiraGTx has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MeiraGTx | 1 | 1 | 5 | 1 | 2.75 |
| Connect Biopharma | 1 | 0 | 3 | 1 | 2.80 |
MeiraGTx presently has a consensus target price of $25.67, suggesting a potential upside of 175.39%. Connect Biopharma has a consensus target price of $8.67, suggesting a potential upside of 243.92%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than MeiraGTx.
Earnings and Valuation
This table compares MeiraGTx and Connect Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MeiraGTx | $81.39 million | 9.33 | -$114.20 million | ($1.42) | -6.56 |
| Connect Biopharma | $60,000.00 | 2,373.84 | -$55.48 million | ($1.00) | -2.52 |
Connect Biopharma has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Connect Biopharma beats MeiraGTx on 9 of the 14 factors compared between the two stocks.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
